Description: An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate
Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies.
Mechanism of Action: Anti-PD-1 being given in combination with LAG 3 inhibitor (SYM22- ARM A) or TIM3 inhibitor (SYM23- ARM B)
Target Patient Population: Awaiting recruitment to biliary tract cancers – intra and/or extrahepatic cholangiocarcinoma and gall bladder cancers. Sub study 1 – PD1 + LAG3 inhibitor or PD 1 + TIM3 inhibitor. Sub study 2 – will use irinotecan + PD1 + TIM3 inhibitors in triplet combination
Study Design: Drug is given IV every 2 weeks